REVOLUTION MEDICINES INC (1RVMD.MI) Fundamental Analysis & Valuation

BIT:1RVMD • US76155X1000

83 EUR
-17 (-17%)
Last: Jan 29, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This 1RVMD.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, 1RVMD scores 3 out of 10 in our fundamental rating. 1RVMD was compared to 75 industry peers in the Biotechnology industry. The financial health of 1RVMD is average, but there are quite some concerns on its profitability. 1RVMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. 1RVMD.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1RVMD has reported negative net income.
  • In the past year 1RVMD has reported a negative cash flow from operations.
  • In the past 5 years 1RVMD always reported negative net income.
  • In the past 5 years 1RVMD always reported negative operating cash flow.
1RVMD.MI Yearly Net Income VS EBIT VS OCF VS FCF1RVMD.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -26.65%, 1RVMD is in line with its industry, outperforming 52.94% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -37.58%, 1RVMD is in the better half of the industry, outperforming 61.18% of the companies in the same industry.
Industry RankSector Rank
ROA -26.65%
ROE -37.58%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
1RVMD.MI Yearly ROA, ROE, ROIC1RVMD.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 1RVMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1RVMD.MI Yearly Profit, Operating, Gross Margins1RVMD.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. 1RVMD.MI Health Analysis

2.1 Basic Checks

  • 1RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 1RVMD has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 1RVMD has been increased compared to 5 years ago.
  • 1RVMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1RVMD.MI Yearly Shares Outstanding1RVMD.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1RVMD.MI Yearly Total Debt VS Total Assets1RVMD.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 15.69 indicates that 1RVMD is not in any danger for bankruptcy at the moment.
  • 1RVMD has a better Altman-Z score (15.69) than 91.76% of its industry peers.
  • 1RVMD has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.16, 1RVMD is doing good in the industry, outperforming 63.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 15.69
ROIC/WACCN/A
WACC8.86%
1RVMD.MI Yearly LT Debt VS Equity VS FCF1RVMD.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

  • 1RVMD has a Current Ratio of 8.05. This indicates that 1RVMD is financially healthy and has no problem in meeting its short term obligations.
  • 1RVMD has a Current ratio of 8.05. This is amongst the best in the industry. 1RVMD outperforms 89.41% of its industry peers.
  • 1RVMD has a Quick Ratio of 8.05. This indicates that 1RVMD is financially healthy and has no problem in meeting its short term obligations.
  • 1RVMD has a Quick ratio of 8.05. This is amongst the best in the industry. 1RVMD outperforms 89.41% of its industry peers.
Industry RankSector Rank
Current Ratio 8.05
Quick Ratio 8.05
1RVMD.MI Yearly Current Assets VS Current Liabilites1RVMD.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. 1RVMD.MI Growth Analysis

3.1 Past

  • The earnings per share for 1RVMD have decreased strongly by -44.01% in the last year.
  • The Revenue for 1RVMD has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.31% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 456.14% on average over the next years. This is a very strong growth
EPS Next Y-59.94%
EPS Next 2Y-37.65%
EPS Next 3Y-19.33%
EPS Next 5Y14.31%
Revenue Next Year1279.08%
Revenue Next 2Y982.92%
Revenue Next 3Y812.44%
Revenue Next 5Y456.14%

3.3 Evolution

1RVMD.MI Yearly Revenue VS Estimates1RVMD.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
1RVMD.MI Yearly EPS VS Estimates1RVMD.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. 1RVMD.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1RVMD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1RVMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1RVMD.MI Price Earnings VS Forward Price Earnings1RVMD.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1RVMD.MI Per share data1RVMD.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • 1RVMD's earnings are expected to decrease with -19.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-37.65%
EPS Next 3Y-19.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1RVMD.MI Dividend Analysis

5.1 Amount

  • No dividends for 1RVMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1RVMD.MI Fundamentals: All Metrics, Ratios and Statistics

REVOLUTION MEDICINES INC

BIT:1RVMD (1/29/2026, 7:00:00 PM)

83

-17 (-17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-02
Inst Owners100.45%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap16.05B
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Analysts87.41
Price Target100.64 (21.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.02%
Min EPS beat(2)-12.79%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-9.21%
Min EPS beat(4)-12.79%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-7.65%
EPS beat(12)4
Avg EPS beat(12)-2.45%
EPS beat(16)6
Avg EPS beat(16)-2.06%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)45.64%
PT rev (3m)N/A
EPS NQ rev (1m)1.5%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.01%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)34.87%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.85
P/tB 12.4
EV/EBITDA N/A
EPS(TTM)-4.38
EYN/A
EPS(NY)-5.74
Fwd EYN/A
FCF(TTM)-3.41
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS0
BVpS7
TBVpS6.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.65%
ROE -37.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 277.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.05
Quick Ratio 8.05
Altman-Z 15.69
F-Score1
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)158.77%
Cap/Depr(5y)142.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
EPS Next Y-59.94%
EPS Next 2Y-37.65%
EPS Next 3Y-19.33%
EPS Next 5Y14.31%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1279.08%
Revenue Next 2Y982.92%
Revenue Next 3Y812.44%
Revenue Next 5Y456.14%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.61%
EBIT Next 3Y-28.97%
EBIT Next 5Y7.47%
FCF growth 1Y-158.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.07%
OCF growth 3YN/A
OCF growth 5YN/A

REVOLUTION MEDICINES INC / 1RVMD.MI FAQ

What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (1RVMD.MI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 1RVMD.MI.


What is the valuation status for 1RVMD stock?

ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (1RVMD.MI). This can be considered as Overvalued.


Can you provide the profitability details for REVOLUTION MEDICINES INC?

REVOLUTION MEDICINES INC (1RVMD.MI) has a profitability rating of 1 / 10.